54.43
-4.18 (-7.13%)
| Penutupan Terdahulu | 58.61 |
| Buka | 59.16 |
| Jumlah Dagangan | 4,575,718 |
| Purata Dagangan (3B) | 1,575,073 |
| Modal Pasaran | 5,281,457,152 |
| Harga / Pendapatan (P/E TTM) | 23.26 |
| Harga / Pendapatan (P/E Ke hadapan) | 6.80 |
| Harga / Jualan (P/S) | 3.09 |
| Harga / Buku (P/B) | 3.46 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Apr 2025 - 5 May 2025 |
| Margin Keuntungan | 12.37% |
| Margin Operasi (TTM) | 24.56% |
| EPS Cair (TTM) | 2.34 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 65.90% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 248.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 87.90% |
| Nisbah Semasa (MRQ) | 4.20 |
| Aliran Tunai Operasi (OCF TTM) | -205.79 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -445.48 M |
| Pulangan Atas Aset (ROA TTM) | 3.77% |
| Pulangan Atas Ekuiti (ROE TTM) | 19.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Sarepta Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 1.50 |
|
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 4.41% |
| % Dimiliki oleh Institusi | 92.27% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Casdin Capital, Llc | 31 Dec 2024 | 1,073,500 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 183.00 (Needham, 236.21%) | Beli |
| Median | 107.00 (96.58%) | |
| Rendah | 75.00 (HC Wainwright & Co., 37.79%) | Pegang |
| Purata | 123.00 (125.98%) | |
| Jumlah | 4 Beli, 4 Pegang | |
| Harga Purata @ Panggilan | 63.79 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 11 Apr 2025 | 182.00 (234.37%) | Beli | 51.03 |
| Wells Fargo | 11 Apr 2025 | 115.00 (111.28%) | Beli | 51.03 |
| HC Wainwright & Co. | 07 Apr 2025 | 75.00 (37.79%) | Pegang | 52.40 |
| 04 Apr 2025 | 75.00 (37.79%) | Pegang | 54.43 | |
| Needham | 03 Apr 2025 | 183.00 (236.21%) | Beli | 58.61 |
| 18 Mar 2025 | 202.00 (271.12%) | Beli | 73.54 | |
| RBC Capital | 31 Mar 2025 | 87.00 (59.84%) | Pegang | 63.82 |
| 27 Feb 2025 | 161.00 (195.79%) | Beli | 103.06 | |
| Scotiabank | 20 Mar 2025 | 80.00 (46.98%) | Pegang | 73.45 |
| 07 Mar 2025 | 105.00 (92.91%) | Pegang | 103.03 | |
| Cantor Fitzgerald | 19 Mar 2025 | 163.00 (199.47%) | Beli | 79.97 |
| 18 Mar 2025 | 163.00 (199.47%) | Beli | 73.54 | |
| Deutsche Bank | 19 Mar 2025 | 99.00 (81.88%) | Pegang | 79.97 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |